The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Why Provention Bio Is in My Portfolio

Contributed Opinion
  ()
Orphan drug and breakthrough therapy status, which could mean this company's lead candidate is on the FDA fast track, translates to huge opportunities for both those suffering from diabetes and investors, says Daniel Carlson of Tailwinds Research. read more >

Retrophin Shares Fall 30% on Failed Phase 3 FORT Study

  ()
Shares of Retrophin fell to a 52-week low on the news that topline results from its fosmetpantotenate Phase 3 FORT Study for PKNA treatment failed to meet expectations. read more >

'Data Readouts Approaching in Two Pivotal Trials' for Biopharma Targeting Unmet Needs

Research Report
  ()
The next steps for each of the programs are outlined in a Dawson James Securities report. read more >

Analyst Upgrade Ignites Duchenne's Muscular Dystrophy Research Firm's Shares

  ()
Solid Biosciences' shares are up by more than 40% after Chardan Capital Markets upgraded the firm's shares from "neutral" to "buy" and raised its price target from $7.50 to $10.00/share. read more >

Deciphera's Shares Open 115% Higher on Phase 3 Ripretinib Results

  ()
Deciphera Pharmaceuticals announced positive top-line results from the INVICTUS pivotal phase 3 clinical study of ripretinib in patients with advanced gastrointestinal stromal tumors. read more >

Amgen Shares React Favorably to Enbrel Patent Case Victory

  ()
Amgen shares traded 5–6% higher on news that the company has won its Enbrel (etanercept) patent court case. read more >

Biotech's DMD Therapeutic 'Solidifies the Ground for Potential Pivotal Design'

Research Report
  ()
The latest development concerning this clinical asset and other Q2/19 highlights are provided in an H.C. Wainwright & Co. report. read more >

Puma Biotech Shares Up More Than 20% on Q2 Earnings and Breast Cancer Drug Sales

  ()
Shares in Puma Biotechnology traded 20% higher after the company released Q2/19 earnings and reported positive NERLYNX revenue growth. read more >

Avedro Shares Looking Up 35% with Glaukos Merger

  ()
Avedro Inc. and Glaukos Corp. announced that the firms' boards of directors have executed a definitive merger agreement. The all-stock deal is expected to close in Q4/19. read more >

Guardant Health Reports Quarterly Revenue Up 178%

  ()
Guardant Health Inc. reported strong growth for Q2/19 versus the same period last year and raised its full-year 2019 revenue guidance to $180–190 million. read more >

Allakos Shares Double on AK002 Phase 2 Results and Earnings

  ()
Allakos Inc. shares soared as the company reported Q2/19 earnings and announced positive results from its phase 2 study for its AK002 inhibitor used in the treatment of eosinophil and mast cell related diseases. read more >

Gaia Grow Corp. Plants 1,494 Acres of Hemp in Canada and Plans First Harvest in 2 Months

Contributed Opinion
  ()
Gaia Grow Corp. CEO Frederick Pels speaks with Peter Epstein of Epstein Research on the day his company begins trading on the TSX Venture Exchange. read more >

Led by Sales of HETLIOZ, Vanda Increases Quarterly Revenues by 25%

  ()
Shares of Vanda Pharmaceuticals traded nearly 30% higher after the company released Q2/19 earnings and positive sales trends for both HETLIOZ and Fanapt. read more >

EMA Opinion Bodes Well for Biopharma's Drug Getting Orphan Status

Research Report
  ()
The designation, opinion and asset are discussed in a ROTH Capital Partners report. read more >

Mylan Gets a Shot in the Arm with Pfizer Merger Deal

  ()
EpiPen manufacturer Mylan N.V. announced that the company will merge with Pfizer Inc.'s Upjohn Division, which holds Pfizer's off-patent branded and generic drugs, forming a new company. read more >

Anixa Licenses Another Potential Blockbuster

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research discusses a major collaboration with the Cleveland Clinic for his top pick stock of the year. read more >

Edwards Lifesciences Gets a Charge on Positive Q2 Earnings Report

  ()
Edwards Lifesciences is trading higher after reporting higher than expected adjusted earnings for Q2/19. The company estimates that the FDA will approve its SAPIEN 3 valve and SAPIEN 3 Ultra system in Q3/19. read more >

Biotech Firm ''Creating Innovative Solutions' for Female Health

Research Report
  ()
The company's most advanced assets are discussed in a Dawson James Securities report. read more >

Biopharma's New License Agreement with Gilead 'Brings Strong Validation and Economics'

Research Report
  ()
The specifics and benefits of the deal are discussed in an H.C. Wainwright & Co. report. read more >

Interim Data Indicate Multiantigen Cell Therapy in Solid Tumors 'Just Might Work'

Research Report
  ()
The immuno-oncology company's findings are reviewed in a ROTH Capital Partners report. read more >
News Update

Biopharma Presents Data on Its Therapeutic Candidates at Alzheimer's Conference

News Update
  ()
The company discussed both its Alzheimer's disease and ALS programs. read more >
News Update

Biopharma Licenses Sustained Release Technology to Gilead for HIV Product

News Update
  ()
The two California-based companies will collaborate on specific related development activities. read more >
News Update

Biopharma Receives PDUFA Goal Date for Nonopioid Pain Drug

News Update
  ()
The FDA deemed the firm's submission for analgesic approval complete. read more >

Top Pick Status Given to Small-Cap with Pain Drug Candidate

Research Report
  ()
The primary reason for the rating—upcoming trial results—is discussed in an Echelon Wealth Partners report. read more >

Seattle Genetics Shares Head Higher After Positive Earnings and ADCETRIS Sales Expansion

  ()
Seattle Genetics announced a 28.3% increase in net sales for its second quarter 2019 powered by ADCETRIS sales along with a promising pipeline. read more >
Showing Results: 1 to 25 of 96 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe